Expert Review of Gastroenterology & Hepatology最新文献_第5页

The role of videocapsule endoscopy in the diagnosis and follow-up of celiac disease: a scoping review. 视频胶囊内镜在乳糜泻诊断和随访中的作用：范围综述。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-10-01 Epub Date: 2024-11-04 DOI: 10.1080/17474124.2024.2422372

Roberta Elisa Rossi, Valeria Poletti, Benedetta Masoni, Angelo Zullo, Matteo Colombo, Cesare Hassan, Alessandro Repici

{"title":"The role of videocapsule endoscopy in the diagnosis and follow-up of celiac disease: a scoping review.","authors":"Roberta Elisa Rossi, Valeria Poletti, Benedetta Masoni, Angelo Zullo, Matteo Colombo, Cesare Hassan, Alessandro Repici","doi":"10.1080/17474124.2024.2422372","DOIUrl":"10.1080/17474124.2024.2422372","url":null,"abstract":"Introduction: Videocapsule endoscopy (VCE) may be a complementary tool in the diagnosis of celiac disease (CD) in cases with equivocal findings and in the follow-up of complicated cases. We aimed to summarize the literature on the utilization of VCE in CD diagnosis/follow-up.Methods: A computerized literature search was performed to identify pertinent articles published between January 2010 and January 2024.Results: Three studies focused on VCE in diagnosing CD, involving a total of 186 patients. VCE was performed due to small bowel atrophy with negative serology (19 patients), positive serology with negative histology (40 patients), contraindications/refusal to undergo esophagogastroduodenoscopy (6 patients), high clinical suspicion of CD despite negative serology and/or small bowel atrophy (99 patients), research purpose (22 patients). Twenty studies focused on the follow-up, involving a total of 1337 patients. VCE was performed due to positive serology despite GFD (64 patients), persistent symptoms (389 patients), known/suspected refractory CD-RCD (448 patients), not specified (436 patients). VCE revealed RCD in 243 patients, ulcerative jejunoileitis in 32, T-cell lymphoma in 18, small bowel tumor in one.Conclusions: VCE may play a role in patients with equivocal CD diagnosis and in those with suspected complications, particularly RCD. Further studies are warranted to draw more solid conclusions.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"673-679"},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Principle of sample size calculation in gastroenterology research: a practical guide for clinicians. 胃肠病学研究样本量计算原则：临床医师实用指南》。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-10-01 Epub Date: 2024-10-16 DOI: 10.1080/17474124.2024.2416239

Antonio Facciorusso, Viktor Domislovic, Lorenzo Fuccio, Ivo Boskoski, Cristiano Spada, Gabriele Capurso, Marianna Arvanitakis, Marcello Maida

{"title":"Principle of sample size calculation in gastroenterology research: a practical guide for clinicians.","authors":"Antonio Facciorusso, Viktor Domislovic, Lorenzo Fuccio, Ivo Boskoski, Cristiano Spada, Gabriele Capurso, Marianna Arvanitakis, Marcello Maida","doi":"10.1080/17474124.2024.2416239","DOIUrl":"10.1080/17474124.2024.2416239","url":null,"abstract":"Introduction: A proper sample size calculation enables to conduct adequately powered randomized controlled trials (RCTs) and to provide a valid assessment of a specific clinical question.Areas covered: In the current manuscript, we tried to provide the reader with an easy guide on the principles of sample size calculation in RCTs, tailored specifically to the context of gastroenterology and hepatology. The basics of sample size calculation were commented with a description of some of the main methods, including the calculation of the non-inferiority margin for non-inferiority RCTs and the calculation of the minimum clinically important difference (MCID). Some examples from the gastroenterology literature were also provided.Expert opinion: Collaborating with a biostatistician can provide valuable insights into the nuances of sample size calculation and study design. However, it is crucial that the clinicians understand the basics of calculating sample size, so they could provide valuable input in designing the study from a clinical point of view.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"561-565"},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interrupting inflammatory bowel disease therapy: why, who, when and how to consider medication holidays. 中断炎症性肠病治疗：为什么、谁、何时以及如何考虑药物假期。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-10-01 Epub Date: 2024-10-18 DOI: 10.1080/17474124.2024.2412048

Joëlle St-Pierre, Asher Shafrir, David T Rubin

{"title":"Interrupting inflammatory bowel disease therapy: why, who, when and how to consider medication holidays.","authors":"Joëlle St-Pierre, Asher Shafrir, David T Rubin","doi":"10.1080/17474124.2024.2412048","DOIUrl":"10.1080/17474124.2024.2412048","url":null,"abstract":"Introduction: Medication holidays in inflammatory bowel disease (IBD) offer a potential means to balance disease management, costs, and quality of life. This concept is increasingly relevant in light of the chronic nature of IBD, the cumulative side effects associated with long-term pharmacotherapy, and the evolving treatment landscape that now includes a large armamentarium of effective induction, maintenance, and rescue therapies paired with disease monitoring tools that enable early intervention.Areas covered: This review critically examines the rationale, implementation, and risks of medication holidays in IBD. Recent evidence is reviewed to help guide the risks of relapse involved with cessation of therapy. The selection criteria for patients, the necessary monitoring protocols, and strategies for managing potential relapses are outlined.Expert opinion: Despite the potential benefits, medication holidays in IBD involve significant risks and require careful patient selection and active management. Current research highlights a need for improved predictive models and a deeper understanding of patient-specific outcomes and consequences. The future of medication holidays will depend heavily on advancements in noninvasive monitoring technologies and more personalized approaches to therapy. Ultimately, establishing clearer guidelines for safely conducting medication holidays will be crucial in integrating this strategy into routine clinical practice.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"587-596"},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in target drugs and immunotherapy for biliary tract cancer. 胆道癌靶向药物和免疫疗法的进展。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-10-01 Epub Date: 2024-11-15 DOI: 10.1080/17474124.2024.2416230

Chiara Deiana, Chiara Ricci, Mahrou Vahabi, Mahsoem Ali, Giovanni Brandi, Elisa Giovannetti

{"title":"Advances in target drugs and immunotherapy for biliary tract cancer.","authors":"Chiara Deiana, Chiara Ricci, Mahrou Vahabi, Mahsoem Ali, Giovanni Brandi, Elisa Giovannetti","doi":"10.1080/17474124.2024.2416230","DOIUrl":"10.1080/17474124.2024.2416230","url":null,"abstract":"Introduction: After years of treatment stagnation in biliary tract cancers (BTC), there has been a notable shift with the emergence of targeted therapies and immunotherapy, leading to substantial progress in tackling this aggressive disease.Areas covered: We provide a comprehensive overview of the target therapies that are already part of the treatment algorithm for BTC, such as FGFR, IDH, and HER2 inhibitors. Additionally, we delve into some less known targets that are being explored, such as KRAS proto-oncogene, MAPK cascade, PI3K/AKT/mTOR pathway and novel molecules directed against P53, claudin, histones, and mitochondrial metabolism. Furthermore, we discuss agnostic drugs and analyze the efficacy data available for BTC specifically. We also examine the expanding world of immunotherapy, with an eye on predictive factors of response for immune checkpoint inhibitors, and on novel immune drugs such as chimeric antigen receptor (CAR)-T and vaccines.Expert opinion: In the expert opinion, we discuss the problem of the scarcity of patients eligible for target therapies and how can clinical trials be designed to overcome this challenge. We also summarize the most promising trials that have the potential to change clinical practice both for immunotherapies and target drugs.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"605-630"},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic drug monitoring in inflammatory bowel disease: recent developments. 炎症性肠病的治疗药物监测：最新进展。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-10-01 Epub Date: 2024-10-09 DOI: 10.1080/17474124.2024.2409300

Xavier Roblin, Robert D Little, Nicolas Mathieu, Stephane Paul, Stephane Nancey, Mathide Barrau, Miles P Sparrow

{"title":"Therapeutic drug monitoring in inflammatory bowel disease: recent developments.","authors":"Xavier Roblin, Robert D Little, Nicolas Mathieu, Stephane Paul, Stephane Nancey, Mathide Barrau, Miles P Sparrow","doi":"10.1080/17474124.2024.2409300","DOIUrl":"10.1080/17474124.2024.2409300","url":null,"abstract":"Introduction: Therapeutic Drug Monitoring (TDM) has an important role in the management of inflammatory bowel disease (IBD) patients on infliximab (IFX) or adalimumab and is recommended in IBD patients presenting a loss of response under anti TNF agent. But, TDM was not recommended for others biotherapies.Areas covered: Analyzing all publications about TDM and biologics in IBD patients, we reported the major results for each biotherapy.Expert opinion: Emerging data suggest that TDM will probably be similarly useful forIFX SC. In contrast, there is no demonstrated clinical benefit to the use of TDM with golimumab. For vedolizumab results for the use of both reactive and proactive TDM are discordant. For ustekinumab, data supports the existence of an exposure response relationship, albeit of a lesser magnitude than with anti-TNF agents. Finally, recent data from small case series suggests that TDM could be valuable in optimizing anti-IL23 agents, particularly risankizumab, but this requires further clarification. Consistent with the new concept of 'proactive' strategy, recent data support the utility of dashboard-driven model informed precision dosing (MIDP) of anti-TNF agents, in particular infliximab. Dashboards are software systems using Bayesian population pharmacokinetic modelling to individualize recommendations for target drug levels.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"575-586"},"PeriodicalIF":3.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gastroesophageal reflux disease in preterm infants: unmet needs. 早产儿胃食管反流病：尚未满足的需求。

IF 3.9 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-09-18 DOI: 10.1080/17474124.2024.2407116

Y Vandenplas,K Huysentruyt

{"title":"Gastroesophageal reflux disease in preterm infants: unmet needs.","authors":"Y Vandenplas,K Huysentruyt","doi":"10.1080/17474124.2024.2407116","DOIUrl":"https://doi.org/10.1080/17474124.2024.2407116","url":null,"abstract":"INTRODUCTION. Many preterm present somatic symptoms including aerodigestive and cardiorespiratory manifestations, in combination with irritability and/or distress, which are often attributed to gastroesophageal reflux (GER), albeit for unclear reasons.AREAS COVEREDWe searched in PubMed, Google Scholar, and MEDLINE for guidelines, reviews and randomized controlled trials up to March 2024.EXPERT OPINIONThe diagnosis of GER-disease (GERD) in preterm is challenged because manifestations are atypical and diagnostic investigations difficult and not devoid of risk for adverse events. In case of vomiting or regurgitation, GER as a consequence of anatomical or metabolic conditions should be considered. Although many preterm infants are treated with proton pump inhibitors, this is seldom needed. Low quality evidence for alginates is available, but needs further evaluation. There is a need for an effective and safe prokinetic favoring esophageal clearance, increasing lower esophageal sphincter pressure and stimulating gastric emptying. Non-drug treatment such as feeding adaptations (volume, duration, composition) and positional changes are insufficiently applied. Thickened formula is not indicated in preterm babies. In case none of the above recommendations did result in sufficient improvement, and if documentation of acid GER is not possible, a 2-4 week trial of a proton pump inhibitor is acceptable.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":"30 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142254138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Esophageal lymphocytosis: exploring the knowns and unknowns of this pattern of esophageal injury 食管淋巴细胞增多症：探索这种食管损伤模式的已知和未知因素

IF 3.9 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-09-16 DOI: 10.1080/17474124.2024.2385493

Laoise C. Coady, Kieran Sheahan, Ian S. Brown, Fátima Carneiro, Anthony J. Gill, Priyanthi Kumarasinghe, Ryoji Kushima, Gregory Y. Lauwers, Rish K. Pai, Neil A. Shepherd, Tomas Slavik, Amitabh Srivastava, Cord Langner

引用次数: 0

Managing bile acid diarrhea: aspects of contention. 处理胆汁酸腹泻：争议的各个方面。

IF 3.9 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-09-12 DOI: 10.1080/17474124.2024.2402353

Julian R F Walters,Rafid Sikafi

{"title":"Managing bile acid diarrhea: aspects of contention.","authors":"Julian R F Walters,Rafid Sikafi","doi":"10.1080/17474124.2024.2402353","DOIUrl":"https://doi.org/10.1080/17474124.2024.2402353","url":null,"abstract":"INTRODUCTIONBile acid diarrhea is a common cause of bowel symptoms and often goes unrecognized or misdiagnosed. Many aspects of management remain contentious.AREAS COVEREDThe primary, idiopathic condition should be suspected in people with functional diarrhea or diarrhea-predominant irritable bowel syndrome. Secondary causes include ileal resection, inflammation, and post-cholecystectomy. Diagnostic tests vary globally, being unavailable in many countries, and further refinement of testing strategy is needed. Management is usually long-term symptom control, rather than reversal of the causative factors, which are still being defined. Bile acid sequestrants remain the main drugs used. They are relatively inexpensive, and better-quality data is now available for colesevelam. However optimal use, including timing and formulation, needs clarification. The GLP-1 receptor agonist, liraglutide, is also effective, although mechanisms of action and whether this effect is common to other class members is unclear. They are more expensive, and availability varies. FXR agonists can also be effective but require further validation. The role of dietary factors in symptom development is a major patient concern, needing more formal studies.EXPERT OPINIONTo build on recent findings, bile acid diarrhea needs further investment into causes, diagnosis and therapy to guide present and future patient care.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":"20 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142214492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CEUS compared with CECT, MRI, and FDG-PET/CT for diagnosing CRC liver metastases: a diagnostic test accuracy systematic review and meta-analysis. CEUS与CECT、MRI和FDG-PET/CT诊断CRC肝转移的比较：诊断测试准确性系统回顾和荟萃分析。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-09-01 Epub Date: 2024-09-25 DOI: 10.1080/17474124.2024.2407973

Martin Lund, Thomas A Bjerre, Henning Grønbæk, Frank V Mortensen, Per Kragh Andersen

{"title":"CEUS compared with CECT, MRI, and FDG-PET/CT for diagnosing CRC liver metastases: a diagnostic test accuracy systematic review and meta-analysis.","authors":"Martin Lund, Thomas A Bjerre, Henning Grønbæk, Frank V Mortensen, Per Kragh Andersen","doi":"10.1080/17474124.2024.2407973","DOIUrl":"10.1080/17474124.2024.2407973","url":null,"abstract":"Objective: To determine the diagnostic accuracy of contrast-enhanced ultrasound (CEUS) compared with contrast-enhanced computed tomography (CECT), magnetic resonance imaging (MRI), and Fluorine-18-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for diagnosing suspected liver metastases in patients with newly diagnosed colorectal cancer (CRC).Methods: The meta-analysis using the bivariate model included studies on patients with newly diagnosed CRC only and excluded patients with non-CRC liver metastases, known liver metastases, patients treated with chemotherapy and local treatments, e.g. hepatic resection or radiofrequency ablation. We used QUADAS-2 to assess the methodological quality of the studies.Results: We included 32 studies, 6 studies evaluated the accuracy of CEUS (n = 937 participants), 26 studies evaluated CECT (n = 2,582), 8 studies evaluated MRI (n = 564) and 6 studies evaluated FDG-PET/CT (n = 813). Sensitivity: FDG-PET/CT 94.4% [95% CI: 90.7-98.1%], MRI 92.9% [95% CI: 88.8-97.0%], CEUS 86.1% [95% CI: 78.0-94.3%] and CECT 84.6% [95% CI: 79.3-89.9%]. Specificity FDG-PET/CT 97.9% [95% CI: 95.9-99.9%], CEUS 96.1% [95% CI: 93.6-98.6%], MRI 94.4% [95% CI: 90.5-98.3%], and CECT 94.3% [95% CI: 91.8-96.8%].Conclusion: FDG-PET/CT had significantly higher sensitivity and specificity than CECT, and significantly higher sensitivity than CEUS. MRI had a significantly higher sensitivity than CEUS, but a lower non-significant specificity. CECT had the lowest sensitivity and specificity.Prospero registration details: CRD42017055015 and CRD42017082996.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"541-549"},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intra-arterial locoregional therapies for intrahepatic cholangiocarcinoma. 肝内胆管癌的动脉内局部疗法。

IF 3.8 3区医学

Expert Review of Gastroenterology & Hepatology Pub Date : 2024-09-01 Epub Date: 2024-09-17 DOI: 10.1080/17474124.2024.2402358

Sandhya Patel, Alina Hasanain, Adam Fang, Mohammad Mahdi Khavandi, Trevor Mathias, Emil I Cohen, Vahid Etezadi, Saher S Sabri, Juan C Camacho, Hooman Yarmohammadi, Filip Banovac, Aiwu R He, Pejman Radkani, Peiman Habibollahi, Nariman Nezami

{"title":"Intra-arterial locoregional therapies for intrahepatic cholangiocarcinoma.","authors":"Sandhya Patel, Alina Hasanain, Adam Fang, Mohammad Mahdi Khavandi, Trevor Mathias, Emil I Cohen, Vahid Etezadi, Saher S Sabri, Juan C Camacho, Hooman Yarmohammadi, Filip Banovac, Aiwu R He, Pejman Radkani, Peiman Habibollahi, Nariman Nezami","doi":"10.1080/17474124.2024.2402358","DOIUrl":"10.1080/17474124.2024.2402358","url":null,"abstract":"Introduction: Intrahepatic cholangiocarcinoma (ICC) is the 2nd most common primary liver malignancy. For nonsurgical candidates, the primary treatment option is systemic chemotherapy, which can be combined with locoregional therapies to enhance local control. Common intra-arterial locoregional therapies include transarterial hepatic embolization, conventional transarterial chemoembolization, drug-eluting bead transarterial chemoembolization, transarterial radioembolization with Yttrium-90 microspheres, and hepatic artery infusion. This article aims to review the latest literature on intra-arterial locoregional therapies for treating ICC.Areas covered: A literature search was conducted on PubMed using keywords: intrahepatic cholangiocarcinoma, intra-arterial locoregional therapy, embolization, chemoembolization, radioembolization, hepatic artery infusion, and immunotherapy. Articles from 2008 to 2024 were reviewed. Survival data from retrospective and prospective studies, meta-analyses, and clinical trials were evaluated.Expert opinion: Although no level I evidence supports the superiority of any specific intra-arterial therapy, there has been a shift toward favoring radioembolization. In our expert opinion, radioembolization may offer superior outcomes when performed by skilled operators with meticulous planning and personalized dosimetry, particularly for radiation segmentectomy or treating lobar/bilobar disease in appropriate candidates.","PeriodicalId":12257,"journal":{"name":"Expert Review of Gastroenterology & Hepatology","volume":" ","pages":"505-519"},"PeriodicalIF":3.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0